Stocks-in-depth

In Myriad's analyst day in NYC on September 14, 2015, management discussed the outlook for several new growth drivers, and it addressed challenges faced in its legacy BRCA1/2 hereditary cancer genetic testing franchise.  We explore what's new, the ins and outs of each opportunity, and delve into the intricacies of companion diagnostics.